A Phase 3 interventional study of Maridebart cafraglutide and Placebo in Obesity Disease, sponsored by Amgen. Active, not recruiting at 30 sites in Japan. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing maridebart cafraglutide in Overweight — 8 open to participants now, 15 under way, 10 of them phase 3. maridebart cafraglutide · Overweight.
Among the 25 studies testing maridebart cafraglutide in Overweight, this one is the 13th largest by enrollment, is one of 10 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 5th registered.
3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.
Browse Overweight studies →8 of the 25 studies testing maridebart cafraglutide in Overweight are open now, in 6 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–70
Amgen · Sites in United States, Canada
Ages 18+
Amgen · Sites in United States, Puerto Rico
Ages 18–99
Amgen · Sites in United States, Canada, Japan and 2 more countries
Ages 18–99
Amgen · Sites in United States, Australia, Canada and 2 more countries
Ages 18–99
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 10 started in 2025.
This study's enrollment of 279 is above the median of 78 across 3,132 interventional studies indexed under Overweight.
Median enrollment 279 across the 25 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 25 have an industry lead sponsor. The 1 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
25 studies in Overweight by Amgen: 8 open now, 15 under way, 10 of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 25 studies in Overweight by Amgen, this one is the 13th largest by enrollment, is one of 10 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 5th registered.
Amgen’s Overweight studies by the year they started, since 2023.
9 of the studies testing maridebart cafraglutide in Overweight that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06987695Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | 2027-04-27 |
| NCT07871409Phase 3AmgenHome Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | 2027-06-16 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 25 studies testing maridebart cafraglutide in Overweight, from their registry updates:
Among Amgen’s 25 in Overweight:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For both BMI categories, at least 1 of the weight-related comorbidities must be hypertension, dyslipidemia, or T2DM according to the definitions below:
In the opinion of the investigator, well-motivated and willing to:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive maridebart cafraglutide high dose subcutaneously (SC) for 72 weeks.
Drug: Maridebart cafraglutide
Participants will receive maridebart cafraglutide medium dose SC for 72 weeks.
Drug: Maridebart cafraglutide
Participants will receive maridebart cafraglutide low dose SC for 72 weeks.
Drug: Maridebart cafraglutide
Participants will receive placebo SC for 72 weeks.
Drug: Placebo
Maridebart cafraglutide will be administered SC.
Also known as: AMG 133, MariTide
Placebo will be administered SC.
Percent Change From Baseline in Body Weight at Week 72
Time frame: Baseline and Week 72
Participants Achieving ≥ 5% Reduction in Body Weight From Baseline at Week 72
Time frame: Baseline and Week 72
Change From Baseline in Waist Circumference at Week 72
Time frame: Baseline and Week 72
Participants Achieving ≥ 10% Reduction in Body Weight from Baseline at Week 72
Time frame: Baseline and Week 72
Participants Achieving ≥ 15% Reduction in Body Weight from Baseline at Week 72
Time frame: Baseline and Week 72
Change From Baseline in Body Weight at Week 72
Time frame: Baseline and Week 72
Percent Change From Baseline in Body Weight in Participants Without Type 2 Diabetes Mellitus (T2DM) at Week 72
Time frame: Baseline and Week 72
Percent Change From Baseline in Body Weight in Participants With T2DM at Week 72
Time frame: Baseline and Week 72
Change From Baseline in Body Mass Index (BMI) at Week 72
Time frame: Baseline and Week 72
Participants Achieving ≥ 20% Reduction in Body Weight from Baseline at Week 72
Time frame: Baseline and Week 72
Change From Baseline in Visceral Fat Area (VFA) at Week 72
Time frame: Baseline and Week 72
Participants Achieving VFA < 100 cm^2 in VFA at Week 72
Time frame: Week 72
Percent Change From Baseline in Fasting Total Cholesterol at Week 72
Time frame: Baseline and Week 72
Percent Change From Baseline in Fasting Non-high-density Lipoprotein Cholesterol (non-HDL-C) at Week 72
Time frame: Baseline and Week 72
Percent Change From Baseline in Fasting Low-density Lipoprotein Cholesterol (LDL-C) at Week 72
Time frame: Baseline and Week 72
Percent Change From Baseline in Fasting Triglycerides at Week 72
Time frame: Baseline and Week 72
Percent Change From Baseline in Fasting Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 72
Time frame: Baseline and Week 72
Percent Change From Baseline in Fasting High-density Lipoprotein Cholesterol (HDL-C) at Week 72
Time frame: Baseline and Week 72
Change From Baseline in Systolic Blood Pressure (SBP) at Week 72
Time frame: Baseline and Week 72
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 72
Time frame: Baseline and Week 72
Change From Baseline in Fasting Plasma Glucose at Week 72
Time frame: Baseline and Week 72
Percent Change From Baseline in Fasting Insulin at Week 72
Time frame: Baseline and Week 72
Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72
Time frame: Baseline and Week 72
Percentage of Participants with a Change from Baseline in Glycemic Status at Week 72 for Participants Without T2DM at Baseline
Glycemic status was categorized as: * normoglycemic (fasting plasma glucose \< 100 mg/dL and HbA1c \< 5.7%, in absence of T2DM diagnosis), * prediabetes (fasting plasma glucose 100 - 125 mg/dL or HbA1c 5.7% - 6.4% in the absence of a T2DM diagnosis), * or, T2DM (fasting plasma glucose ≥ 126 mg/dL and HbA1c ≥6.5%).
Time frame: Baseline and Week 72
Participants With T2DM Achieving HbA1c < 7% at Week 72
Time frame: Week 72
Participants With T2DM Achieving HbA1c ≤ 6.5% at Week 72
Time frame: Week 72
Participants With T2DM Achieving HbA1c < 5.7% at Week 72
Time frame: Week 72
Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Physical Function Domain Score at Week 72
The SF-36v2 Acute Physical Function domain score measures an individual's ability to perform daily physical activities, such as walking and climbing stairs, over the past week. It includes 10 items scored on a 3-point Likert scale, with raw scores transformed to a 0-100 scale. Higher scores indicate better physical functioning and fewer limitations due to physical health.
Time frame: Baseline and Week 72
Change from Baseline in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score at Week 72
The IWQOL-Lite-CT is a 20-item questionnaire designed to assess the impact of weight on quality of life in clinical trials. Items are scored on a 5-point Likert scale, with raw scores transformed to a 0-100 scale, where higher scores indicate better quality of life and less weight-related impact.
Time frame: Baseline and Week 72
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to Week 84
Number of Participants Experiencing Serious Adverse Events
Time frame: Up to Week 84
Plasma Concentration of Maridebart Cafraglutide at Week 72
Time frame: Week 72
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.
Of 127 industry-sponsored phase 3 interventional studies under Overweight, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's planned 22 months is close to that.
Counting every sponsor, half of 136 studies reached it within 21 months; a quarter within 17 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maridebart cafraglutide